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Pulmonary arterial hypertension (PAH) remains a devastating illness,
with an average survival that is still less than 5 years. Our understanding
of PAH has evolved from considering it a disease of vasoconstriction, to
recognizing that disordered cellular proliferation and resulting physical
obstruction of the microvascular lumen are the principal causes of the
increased pulmonarymicrovascular resistance. In parallel, insights gained
from less frequent types of PAH, such as the heritable form of idiopathic
PAH and PAH associated with Hereditary Hemorrhagic Telangiectasia,
have highlighted the importance of disordered growth factor signalling in
the origin and pathogenesis of the disease, particularly bymembers of the
transforming growth factor β superfamily, including bone morphogenic
proteins. Moreover, it has become clear that the endothelial cell is central
to the disorder, in terms of abnormal cell signalling, mediators and
proliferation. Emergence of apoptosis-resistant endothelial clones and
change to a neoplastic phenotype are hallmarks of PAH. Endothelial-
derived mediators normally help maintain vascular heath. Abundant
locally-produced prostacyclin and nitric oxide, and low levels of
edothelin-1 normally preserve vascular patency. This balance is reversed
in PAH, with low levels of prostacyclin and nitric oxide, and excess
production of endothelin-1. Therapeutic blockade of endothelin-1 has
resulted in clinical beneﬁt for thousands of patients with PAH, who have
had improvement in functional capacity and fewer clinical deteriorations.
Each generation of endothelin antagonists improves on this track record.
However, none of these agents is curative, and the potential reasons will
be discussed. There is tremendous crosstalk betweenmediator systems in
the vascularwall.With regard to endothelin-1, this is an area that requires
further exploration, in order to understand the triggers for increased
endothelin-1 levels and how to control them in PAH. Recent evidence
suggests important interactions between the bone morphogenic protein
and endothelin-1 systems, which deserve more study. The ultimate goal
would be to suppress endothelin-1 synthesis and eliminate its contribu-
tion to the progression of this disorder.
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Although pulmonary endarterectomy (PEA) can sufﬁciently decrease
pulmonary arterial pressure (PAP) in patients with chronic thrombo-
embolic pulmonary hypertension (CTEPH), not all patients can undergo
PEA because of technical limitations. Several drugs such as endothelin
receptor antagonist to treat pulmonary hypertension have been used to
manage these patients, but sufﬁcient decrease of PAP cannot be
achieved. Balloon catheter would easily reach to surgically inaccessible
lesions and therefore, we hypothesized that balloon pulmonary
angioplasty (BPA) would be an effective treatment option for inoperable
patients with CTEPH. We have treated 162 inoperable patients with
CTEPH (WHO functional class III or IV despite full medical treatment,
mean age 62 years old)with BPA.Mean PAP signiﬁcantly decreased after
BPA (from 44.9 to 24.0 mmHg (P b 0.001)). Forty patients developed
severe reperfusion pulmonary injury after BPA and 5 of themdied during
hospitalization. Additional 3 patients died during follow-up period and
3-year survival rate was 94.4%. Sixty-four out of 132 patients have been
followed up formore than one year after BPA. Decrease ofmean PAPwas
maintained (21.9 mmHg). Thus, BPA would be an effective therapeutic
option in these patients who have otherwise no proven treatment.
doi:10.1016/j.lfs.2013.12.114
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Introduction pulmonary arterial hypertension (PAH) is character-
ized by functional and structural changes in the pulmonary vascula-
ture, and despite the progress of pharmacotherapy, the prognosis of
patients with advanced PAH remains poor. Adipose-derived regener-
ative cell (ADRC) therapy has recently emerged as a novel therapy for
ailments of various organs by promoting cell regeneration at site of
pathology. In this study, we investigated the efﬁcacy of ADRCs therapy
on PAH using monocrotaline (MCT)-induced PAH rat model, and
explored underlying mechanisms.
Methods male Wistar rats were divided into the control, MCT, and
MCT with ADRCs transfusion (M/A) group. Seven million ADRCs were
transfused by intravenous injection at day 7. PAH was evaluated by
measuring acceleration time (AT) and deceleration (Dct) of PA ﬂow
using echocardiography. At day 28, pathological changes in pulmonary
vessels were assessed. The expression of genes associated with PAHwas
analyzed at day 14 by real time RT-PCR. Results Echocardiography
showed that ADRCs therapy inhibited the development of PAH at day 28
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